MedTrace Logo

Hospital Processes Reengineering of Intravenous Thrombolysis in Acute Ischemic Stroke in China

NCT02631317 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2178

Last updated 2016-02-05

No results posted yet for this study

Summary

PROMISE is a prospective, nationwide, multicenter, longitudinal cohort study, focusing on hospital intravenous thrombolysis process reengineering for acute ischemic stroke (AIS). With a proposed "Reengineered Process Framework" for intravenous thrombolysis process by the PROMISE study steering committee, about 30 medical centers enters would be recruited nationwide, and each center would include consecutive AIS patients with an onset-to-door time (ODT) of less than 3.5 h. The investigators hypothesize that the proposed "Reengineered Process Framework" is suitable and feasible for hospitals in mainland of China; the rate of intravenous rt-PA thrombolysis in ischemic stroke patients with an ODT of less than 3.5 h would be more than 20% or be increased by 40% as compared with baseline; the proportion of patients with a door-to-needle (DNT) time of less than 60 min would be more than 20%, or be with an increase by ≥ 40% as compared with baseline.

Conditions

Interventions

BEHAVIORAL

Advance hospital notification by EMS

Advance hospital notification by EMS

BEHAVIORAL

stroke team notification

stroke team notification

BEHAVIORAL

key performance indicators feedback form

a "key performance indicators real-time feedback form" as continuing quality improvement

BEHAVIORAL

standard informed consent procedures

standard informed consent procedures with public poster of thrombolysis

BEHAVIORAL

performance of thrombolysis at CT-room

performance of thrombolysis at CT-room or emergency room

Sponsors & Collaborators

  • First Affiliated Hospital of Jinan University

    lead OTHER

Principal Investigators

  • ANDING XU, Prof · Stroke Center, The First Affiliated Hospital,Jinan University Guanzghou

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-12-31
Completion
2015-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02631317 on ClinicalTrials.gov